Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Poin

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/27/2026

1. ON
2. SYNA
3. SPY
4. MU
5. AAPL
6. VEON
7. DRI
8. RKLB
9. SPCX
10. NKE

Go back to Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Poin

Amarin Corporation (AMRN) PT Raised to $51 at H.C. Wainwright; REDUCE-IT Update is a 'Home run'

November 12, 2018 7:44 AM EST

H.C. Wainwright analyst Andrew Fein raised the price target on Amarin Corporation (NASDAQ: AMRN) to $51.00 (from $31.00) while maintaining a Buy rating.

Fein commented, "The detailed data presentation of the REDUCE-IT trial of Vascepa at this years American Heart Association (AHA) conference in conjunction with the publication in the New English Journal of Medicine (NEJM)... More